DE60203894D1 - Herstellung von nichtkristallinem atorvastatin?calcium - Google Patents

Herstellung von nichtkristallinem atorvastatin?calcium

Info

Publication number
DE60203894D1
DE60203894D1 DE60203894T DE60203894T DE60203894D1 DE 60203894 D1 DE60203894 D1 DE 60203894D1 DE 60203894 T DE60203894 T DE 60203894T DE 60203894 T DE60203894 T DE 60203894T DE 60203894 D1 DE60203894 D1 DE 60203894D1
Authority
DE
Germany
Prior art keywords
atorvastatin
crystalline
calcium
salt
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60203894T
Other languages
English (en)
Other versions
DE60203894T2 (de
Inventor
Gorazd Sorsak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lek Pharmaceuticals dd
Original Assignee
Lek Pharmaceuticals and Chemical Co dd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lek Pharmaceuticals and Chemical Co dd filed Critical Lek Pharmaceuticals and Chemical Co dd
Application granted granted Critical
Publication of DE60203894D1 publication Critical patent/DE60203894D1/de
Publication of DE60203894T2 publication Critical patent/DE60203894T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE60203894T 2001-01-23 2002-01-22 Herstellung von nichtkristallinem atorvastatin?calcium Expired - Lifetime DE60203894T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SI200100010A SI20814A (sl) 2001-01-23 2001-01-23 Priprava amorfnega atorvastatina
SI200110010 2001-01-23
PCT/IB2002/000161 WO2002059087A1 (en) 2001-01-23 2002-01-22 Preparation of non-crystalline atorvastatin calcium

Publications (2)

Publication Number Publication Date
DE60203894D1 true DE60203894D1 (de) 2005-06-02
DE60203894T2 DE60203894T2 (de) 2006-01-19

Family

ID=20432812

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60203894T Expired - Lifetime DE60203894T2 (de) 2001-01-23 2002-01-22 Herstellung von nichtkristallinem atorvastatin?calcium

Country Status (27)

Country Link
US (2) US6750353B2 (de)
EP (1) EP1373202B1 (de)
JP (1) JP4336106B2 (de)
KR (1) KR100882066B1 (de)
CN (1) CN1260213C (de)
AT (1) ATE294159T1 (de)
AU (1) AU2002219455B2 (de)
BG (1) BG108017A (de)
BR (1) BR0206637A (de)
CA (1) CA2435954C (de)
CZ (1) CZ20031988A3 (de)
DE (1) DE60203894T2 (de)
DK (1) DK1373202T3 (de)
EE (1) EE05270B1 (de)
ES (1) ES2240748T3 (de)
HR (1) HRP20030575B1 (de)
HU (1) HU227535B1 (de)
IL (2) IL157068A0 (de)
MX (1) MXPA03006548A (de)
PL (1) PL209428B1 (de)
RS (1) RS51010B (de)
RU (1) RU2324679C2 (de)
SI (2) SI20814A (de)
SK (1) SK286593B6 (de)
UA (1) UA73829C2 (de)
WO (1) WO2002059087A1 (de)
ZA (1) ZA200305307B (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
PL365312A1 (en) 2000-12-27 2004-12-27 Teva Pharmaceutical Industries Ltd Crystalline forms of atorvastatin
WO2002068335A2 (en) * 2001-02-27 2002-09-06 Council Of Scientific And Industrial Research Essential oil composition for potable water disinfection
KR100609371B1 (ko) 2001-06-29 2006-08-08 워너-램버트 캄파니 엘엘씨 Ｒ-(ｒ*,ｒ*)-2-(4-플루오로페닐)-베타,델타-디히드록시-5-(1-메틸에틸)-3-페닐-4-페닐아미노)카르보닐-1ｈ-피롤-1-헵탄산 칼슘염 (2:1) (아토르바스타틴)의 결정질 형태
HU227124B1 (en) * 2001-09-14 2010-07-28 Egis Gyogyszergyar Nyilvanosan Polymorphs of 1-pyrrole derivative, intermediate for the preparation of atorvastatin
JP4422488B2 (ja) 2002-02-19 2010-02-24 テバ ファーマシューティカル インダストリーズ リミティド アトルバスタチンヘミカルシウム溶媒和物の脱溶媒和法及び有機溶媒を本質的に含まないアトルバスタチンヘミカルシウム
ITMI20020907A1 (it) * 2002-04-29 2003-10-29 Chemi Spa Processo di preparazione della forma amorfa del sale di calcio della atorvastatina
CA2385529A1 (en) * 2002-05-21 2003-11-21 Bernard Charles Sherman Stable dosage forms comprising atorvastatin calcium
CA2520740C (en) * 2003-04-11 2012-06-05 Lek Pharmaceuticals D.D. Process for the preparation of amorphous calcium salt of atorvastatin
US7790197B2 (en) 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
WO2005003138A2 (en) 2003-07-02 2005-01-13 EGIS Gyógyszergyár Rt. Process for the preparation of amorphous form of a platelet aggregation inhibitor drug
AU2003247327A1 (en) * 2003-07-15 2005-01-28 Eos Eczacibasi Ozgun Kimyasal Urunler Sanyi Ve Ticaret A.S. Process for the preparation of amortphous atorvastatin calcium without interconversion of any crystalline form
AU2003272082A1 (en) * 2003-10-07 2005-04-21 Biocon Limited Process for the production of atorvastatin calcium
EP1711489B1 (de) * 2003-12-29 2012-12-26 LEK Pharmaceuticals d.d. Verfahren zur herstellung von amorpher (4r-cis)-6-[2-[3-phenyl-4-(phenylcarbamoyl)-2-(4-fluorophenyl)-5-(1-methyl)-pyrrol-1-yl]-2,2-dimethyl-[1,3]-dioxan-4-yl-essigsäure
PT1727795E (pt) 2004-03-17 2012-04-11 Ranbaxy Lab Ltd Processo para a produção de atorvastatina cálcica na forma amorfa
US7875731B2 (en) 2004-05-05 2011-01-25 Pfizer Inc. Salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)Carbonyl]-1H-pyrrole-1-heptanoic acid
HUE029911T2 (en) * 2004-07-16 2017-04-28 Lek Pharmaceuticals Products of atorvastatin calcium oxidative degradation
CA2573771C (en) 2004-07-20 2011-05-10 Warner-Lambert Company Llc Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta., .gamma.-dihydroxy-5-(1-menthylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
WO2006011155A1 (en) * 2004-07-26 2006-02-02 Apollo International Limited One pot process for amorphous atorvastain calcium
JP2008510798A (ja) * 2004-08-27 2008-04-10 バイオコン・リミテッド 非晶質アトルバスタチンカルシウムのための方法
KR20070067175A (ko) 2004-10-28 2007-06-27 워너-램버트 캄파니 엘엘씨 무정형 아토르바스타틴 형성 방법
ES2270722B1 (es) * 2005-09-15 2008-03-01 Ercros Industrial, S.A. Procedimiento para la obtencion de atorvastatina calcica amorfa.
US20090216029A1 (en) * 2005-09-16 2009-08-27 Yatendra Kumar Process for the production of atorvastatin calcium in amorphous form
CA2547216A1 (en) 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
US8084488B2 (en) * 2005-11-21 2011-12-27 Pfizer Inc. Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid magnesium
EP1810667A1 (de) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmazeutische Zusammensetzung enthaltend amorphes Atorvastatin
EP1979313A1 (de) * 2006-01-31 2008-10-15 Jubilant Organosys Limited Verfahren zur herstellung von amorphem atorvastatin-calciumsalz
CN100406438C (zh) * 2006-06-30 2008-07-30 浙江新东港药业股份有限公司 一种无定型阿伐他汀钙的制备方法
US20100113802A1 (en) * 2006-11-02 2010-05-06 Cadila Pharmaceuticals Limited Process for preparing amorphous atorvastatin hemi calcium salt and its itermediate
KR100833439B1 (ko) * 2007-01-02 2008-05-29 씨제이제일제당 (주) 비결정형 아토르바스타틴 칼슘의 개선된 제조방법
EP2211611B1 (de) * 2007-10-17 2014-12-10 Todd F. Ovokaitys Verfahren zum modifizieren des festen aggregatszustands einer verbindung und hiermit hergestellte co-amorphe zusammensetzungen
WO2009139730A1 (en) * 2008-05-13 2009-11-19 Ulkar Kimya San. Ve Tic. A.S. Preparation of novel non-crystalline forms of atorvastatin calcium
KR101050722B1 (ko) 2008-12-02 2011-07-21 대웅바이오 주식회사 무정형 아토르바스타틴 칼슘염의 제조방법
US8115015B2 (en) * 2009-01-26 2012-02-14 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
EP2560951B1 (de) * 2010-04-19 2016-05-25 DSM Sinochem Pharmaceuticals Netherlands B.V. Herstellung von atorvastatin mit geringen etherunreinheiten
HUP1000299A2 (hu) 2010-06-08 2012-02-28 Nanoform Cardiovascular Therapeutics Ltd Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra
CN102796036B (zh) * 2012-09-12 2014-06-04 江苏阿尔法药业有限公司 一种阿托伐他汀钙的制备方法
US10202598B2 (en) 2014-05-30 2019-02-12 Todd Frank Ovokaitys Methods and systems for generation, use, and delivery of activated stem cells
US10384985B2 (en) 2014-06-06 2019-08-20 B.K. Consultants, Inc. Methods and compositions for increasing the yield of, and beneficial chemical composition of, certain plants
US10040728B2 (en) 2014-06-06 2018-08-07 Todd Frank Ovokaitys Methods and compositions for increasing the bioactivity of nutrients
CN113321607A (zh) * 2020-02-28 2021-08-31 北京福元医药股份有限公司沧州分公司 一种阿托伐他汀钙中间体的纯化方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5245047A (en) 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5149837A (en) 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5124482A (en) 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5103024A (en) 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
HRP960313B1 (en) 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
HRP960312B1 (en) * 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
PL193479B1 (pl) * 1995-07-17 2007-02-28 Warner Lambert Co Formy krystaliczne hydratu atorwastatyny, kompozycja farmaceutyczna zawierająca formę krystaliczną I hydratu atorwastatyny oraz jej zastosowanie
US6087511A (en) * 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
IN191236B (de) * 1999-05-25 2003-10-11 Ranbaxy Lab Ltd

Also Published As

Publication number Publication date
CA2435954A1 (en) 2002-08-01
BR0206637A (pt) 2004-08-03
DE60203894T2 (de) 2006-01-19
RU2003124962A (ru) 2005-01-10
EE200300333A (et) 2003-10-15
KR20030077003A (ko) 2003-09-29
SI20814A (sl) 2002-08-31
US6750353B2 (en) 2004-06-15
SK286593B6 (sk) 2009-01-07
SI1373202T1 (sl) 2005-12-31
YU56803A (sh) 2006-05-25
KR100882066B1 (ko) 2009-02-10
US20040072895A1 (en) 2004-04-15
RU2324679C2 (ru) 2008-05-20
US7074940B2 (en) 2006-07-11
AU2002219455B2 (en) 2007-04-26
CZ20031988A3 (cs) 2003-11-12
EE05270B1 (et) 2010-02-15
EP1373202B1 (de) 2005-04-27
JP2005503997A (ja) 2005-02-10
PL209428B1 (pl) 2011-08-31
MXPA03006548A (es) 2004-10-15
HU227535B1 (en) 2011-08-29
RS51010B (sr) 2010-10-31
HRP20030575B1 (en) 2011-10-31
ZA200305307B (en) 2004-07-09
WO2002059087A1 (en) 2002-08-01
BG108017A (bg) 2004-08-31
CN1260213C (zh) 2006-06-21
SK9082003A3 (en) 2003-12-02
EP1373202A1 (de) 2004-01-02
HRP20030575A2 (en) 2005-06-30
UA73829C2 (en) 2005-09-15
ES2240748T3 (es) 2005-10-16
CN1487921A (zh) 2004-04-07
HUP0302797A3 (en) 2009-09-28
IL157068A (en) 2009-09-01
PL361763A1 (en) 2004-10-04
IL157068A0 (en) 2004-02-08
JP4336106B2 (ja) 2009-09-30
US20030109569A1 (en) 2003-06-12
ATE294159T1 (de) 2005-05-15
DK1373202T3 (da) 2005-05-17
CA2435954C (en) 2008-06-03
HUP0302797A2 (hu) 2003-11-28

Similar Documents

Publication Publication Date Title
DE60203894D1 (de) Herstellung von nichtkristallinem atorvastatin?calcium
WO2001096334A3 (en) Heteroarylalkanoic acids as integrin receptor antagonists
ZA9711607B (en) Novel cyclosporin derivatives, their preparation and the pharmaceutical compositions which contain them.
AUPR213700A0 (en) Antiviral agents
TR199901127T2 (xx) Antibakteriyel etkili 6-O-ikameli ketolitler.
ZA9711606B (en) Cyclosporin derivatives, their preparation and the pharmaceutical compositions which contain them.
DK0891325T3 (da) Para-substituerede phenylpropansyrederivater som integrinantagonister
DK0894084T3 (da) Kanelsyrederivater og deres anvendelse som integrinantagonister
CY1108559T1 (el) Αλατα βαλσαρτανης
ATE202337T1 (de) Cyclopropylalkansäurederivate
WO2001096307A3 (en) Cycloalkyl alkanoic acids as integrin receptor antagonists
WO2004096823A3 (en) Novel ketolide derivatives
DK0734383T3 (da) Cykliske amidderivater som neurokinin-A-antagonister
DK0992509T3 (da) Nye makrolid-derivater
WO2001027110A3 (de) Am sechsring substituierte, bicyclische imidazo-3-yl-aminderivate
DK0808303T3 (da) 5-(4-subst.-piperidinyl-1)-3-aryl-pentansyrederivater som tachykininreceptorantagonister
WO2001081316A3 (en) Substituted phenyl farnesyltransferase inhibitors
ATE310010T1 (de) 6-0-substitutierte eryththromycin-verbindungen und verfahrenen zu ihrer herstellung
ATE266029T1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
EA200300272A1 (ru) Новые производные хиназолина, способ их получения и фармацевтические композиции, содержащие их
DE69927997D1 (de) Neuartige pyrimidin-derivate und verfahren zu ihrer herstellung
MX9207204A (es) Preparado farmaceutico y procedimiento para su fabricacion.
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
AP9801235A0 (en) Erythromycin derivatives.
DE60008430D1 (de) Verbindungen mit antithrombotischer wirkung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: LEK PHARMACEUTICALS D.D., LJUBLJANA, SI